Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Discover yearly leaders among index funds and understand how performance shifts across periods, helping you choose resilient options.
27,236 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
A shipping analyst argues that Iran has become a de facto toll gate for the Strait of Hormuz, changing global oil rou...
A $100,000 investment in Dividend Kings targets $5,400 of passive income each year, reflecting durable payouts amid a...
A new Goldman Sachs Asset Management survey shows that even high earners face a squeeze between income and expenses, ...
A sharp one-day drop in ZoomInfo’s shares has investors weighing growth against profitability. This analysis explains...
Bitcoin slumped to a two-week low, dragging a wide swath of altcoins lower as risk-off trading returned this weekend....
Bolt is reshaping its growth plan after a sweeping HR shakeup and large-scale layoffs. The fintech aims to regain spe...
Regulators and banks frame XRP's path as traders debate a remote target. This report lays out what would be required ...
The United States appears to be nearing a practical ceiling in its sanctions campaign against Iran, raising questions...
Stocks climbed as heavyweight tech names posted solid results and ceasefire hopes supported risk appetite, sending th...
In 2026, misfired AI layoff messaging draws public boos and investor scrutiny. This report traces how leaders’ word c...
A Deloitte-recognized fast-growing software company launches a phone-scrolling earnings program, sending shares aroun...